Key result
Pre-hospital statin treatment was not associated with in-hospital MACEs, but was associated with an 8.9% higher adjusted risk of severely obstructive coronary artery disease (OR 1.089).
Why the study?
The dyslipidemia burden, pre-hospital statin use, and their association with CAD severity and in-hospital outcomes in Chinese patients with first ACS remained unclear.
Does pre-hospital statin treatment improve in-hospital outcomes or reduce the severity of coronary artery disease in patients with first acute coronary syndrome?
Observational (n=41,183)
Yes
Does pre-hospital statin treatment improve in-hospital outcomes or reduce the severity of coronary artery disease in patients with first acute coronary syndrome?
Odds Ratio: 1.089 (95% CI 1.01–1.175)
Absolute Event Rate: 31% vs 31.5%
p-value: p=0.028
In patients presenting with their first ACS, pre-hospital statin use was not associated with improved in-hospital outcomes and was paradoxically associated with more severe angiographic coronary disease, likely reflecting confounding by indication.
Statin pretreatment should not alter acute ACS management; observational data leaves open confounding or selection bias in CAD severity.
Background The current burden of dyslipidemia, the pre-hospital application of statins and the association of pre-hospital statins with the severity of coronary artery disease (CAD) and in-hospital outcomes in Chinese patients with first acute coronary syndrome (ACS) are very significant and remain unclear. Methods A total of 41,183 patients who underwent coronary angiography and were diagnosed with ACS for the first time from a nationwide registry study (CCC-ACS) were enrolled. The severity of CAD was assessed using the CAD prognostic index (CADPI). The patients were classified into statin and non-statin groups according to their pre-hospital statin treatment status. Clinical characteristics, CADPI and in-hospital outcomes were compared, and a logistic regression analysis was performed to determine whether pre-hospital statin therapy is associated with in-hospital outcomes and CADPI. A sensitivity analysis was used to further explore the issues above. Results The non-statin group had more in-hospital all-cause deaths (1.2 vs. 0.8%, P = 0.010). However, no association exists between statin pretreatment and in-hospital major adverse cardiovascular events (MACEs) or all-cause deaths in the entire population and subgroups (all P > 0.05). Surprisingly, statin pretreatment was associated with an 8.9% higher risk of severely obstructive CAD (CADPI ≥ 37) (OR, 1.089; 95% CI, 1.010–1.175, P = 0.028), and similar results were observed in subgroups of females, those aged 50 to 75 years, and patients with hypertension. Conclusion Statin pretreatment was not related to MACEs or all-cause death during hospital stay, but it was associated with a higher risk of increased angiographic severity in patients with first ACS.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2023) conducted an observational in First acute coronary syndrome (ACS) (n=41,183). Pre-hospital statin treatment vs. No pre-hospital statin treatment was evaluated on Severely obstructive CAD (CADPI ≥ 37) (OR 1.089, 95% CI 1.010-1.175, p=0.028). Pre-hospital statin treatment was not associated with in-hospital MACEs, but was associated with an 8.9% higher adjusted risk of severely obstructive coronary artery disease (OR 1.089).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: